RELATED STUDY

Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.

Key Findings:  Although, many open questions await to be answered, pharmacological modulation of the (endo)cannabinoid signaling, and restoration of the homeostatic eCB tone of the tissues augur to be very promising future directions in the management of several pathological inflammation-accompanied diseases.

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  Hungary

Year of Pub:  2017


Cannabinoids Studied:  Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified), Pharma THC:CBD

Phytocannabinoid Source:  Not Applicable

Terpenes Studied:  ß-Caryophyllene

Receptors Studied:  CB1, CB2, GPCR 18, GPCR 55, Opioid Receptor Delta, TRPA1, TRPV1, TRPV2, TRPV4, TRPM8, GPCR, TRPs, PPARs

Ligands Studied:  Anti-inflammatory cytokines, Dopamine, Epinephrine, Serotonin, Neurotransmitter (unspecified/other)